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ABSTRACT
Background: Population mean changes from clinical
trials are difficult to apply to individuals in clinical practice.
Responder analysis may be better, but needs validating
for level of response and treatment duration.
Methods: The numbers of patients with pain relief over
baseline (>15%, >30%, >50%, >70%) at 2, 4, 8 and
12 weeks of treatment were obtained using the WOMAC
100 mm visual analogue pain subscale score for each
treatment group in seven randomised placebo-controlled
trials of etoricoxib in osteoarthritis lasting >6 weeks.
Dropouts were assigned 0% improvement from baseline
from then on. The numbers needed to treat (NNTs) were
calculated at each level of response and time point.
Results: 3554 patients were treated with placebo,
etoricoxib 30 mg and 60 mg, celecoxib 200 mg,
naproxen 1000 mg or ibuprofen 2400 mg daily. Response
rates fell with increasing pain relief: 60–80% experienced
minimally important pain relief (>15%), 50–60% moder-
ate pain relief (>30%), 40–50% substantial pain relief
(>50%) and 20–30% extensive pain relief (>70%). NNTs
for etoricoxib, celecoxib and naproxen were stable over
2–12 weeks. Ibuprofen showed lessening of effective-
ness with time.
Conclusion: Responder rates and NNTs are reproducible
for different levels of response over 12 weeks and have
relevance for clinical practice at the individual patient
level. An average 10 mm improvement in pain equates to
almost one in two patients having substantial benefit.
Clinical trials are performed usually for regulatory
purposes, with outcomes typically reported as
statistical comparisons between treatment group
population means. The results of clinical trials can
be difficult to translate into clinical practice. A
report that an intervention shows an average
10 mm reduction more than placebo on a
100 mm visual analogue scale has little immediate
impact.
Moreover, few of us are average. Most drugs
provide a good response in half or fewer of the
patients treated,




7 and tumour necrosis
factor antagonists in rheumatoid arthritis.
8 An 80/
20 rule seems to apply in osteoarthritis, with 80%
of patients experiencing 20% pain relief but only
20% experiencing 80% relief; about half have their
pain halved.
9
Genetic influences help determine the clinical





12 as well as the clinical response
to methotrexate.
13 Pain is driven by complex
pathways of neural mechanisms which are likely
to be different between individuals.
14 Imaging
reveals loss of grey matter in chronic pain above
that found with age alone.
15 16
Average data from skewed distributions can
produce misleading results.
17 Dichotomous respon-
der analyses have been reported previously for
acute
18 and chronic pain.
561 9 The validity of a
dichotomous measure should be established before
being widely used.
20
An added factor contributing to differences in
treatment response observed in clinical practice
compared with a clinical trial is the handling of
dropouts. Commonly, a ‘‘last observation carried
forward’’ technique is used in clinical trials, where
data from patients with good pain control but
intolerable adverse events will still be included in
efficacy calculations using the population mean. In
clinical practice, this same patient would be
considered a treatment failure.
We used individual patient data from seven
randomised placebo-controlled trials in osteoarthri-
tis to investigate the effects of different levels of
pain relief assessed at various time points on
estimates of efficacy.
METHODS
Merck Research Laboratories provided pain
response data from seven randomised placebo-
controlled trials of etoricoxib in osteoarthritis
lasting >6 weeks (protocols 007, 018, 019, 071,
073, 076 and 077).
21–26 PDF copies of the company
clinical trial reports were also available.
We calculated the number of patients in each
treatment group in each trial achieving various
Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT) thresh-
olds of pain relief over baseline of >15% (minimal
benefit), >30% (moderate), >50% (substantial)
27
and >70% which we defined as extensive improve-
ment. These were assessed at 2, 4, 8 and 12 weeks.
All trials lasted 12 weeks except protocol 007
which lasted 6 weeks.
In each study patients were asked, ‘‘During the
last 48 hours, how much pain do you have (1)
walking on a flat surface; (2) going up or down
stairs; (3) at night while in bed; (4) sitting or lying;
(5) standing upright?’’. On a 100 mm visual
analogue scale, patients placed an ‘‘x’’ ranging
from 0 (‘‘no pain’’) to 100 (‘‘extreme pain’’). The
Extended report
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100 mm visual analogue pain subscale score was calculated as
the average of the responses to the five questions.
Criteria used in defining responders included:
c For patients who did not drop out, only actual measured
values were used for calculations. Last observation carried
forward was not used.
c For patients who withdrew for any reason, measurements
made within 7 days of the last dose were used to calculate
the response.
c Thereafter, patients were assigned 0% improvement.
We calculated the number and percentage of responders for
each level of response for each drug and time point and the
number needed to treat (NNT) compared with placebo (with
95% CI).
28 The relative risk with 95% CI was calculated using
the fixed effects model
29 and considered statistically significant
when the 95% CI did not include 1. Statistically significant
differences between NNTs were established using the z test,
30
comparing different drug/dose combinations only in the trials in
which they were used together.
Clinical trial reports were used to obtain, for each active
treatment, the difference between active treatment and placebo
for the WOMAC pain subscale score. This was defined in the
company clinical trial reports as the mean time-weighted
average change from baseline (flare/randomisation visit) over
the 6- or 12-week treatment period ((WOMAC baseline 2
WOMAC treatment average) 2 (WOMAC baseline 2
WOMAC placebo average)). Average results for each treatment
arm were pooled using RevMan 5.0.
RESULTS
Information was available on 3554 patients (two-thirds
women) with an average age of 62 years (see online supple-
ment). Six trials involved patients with osteoarthritis of the
knee or hip and one of the knee only. Osteoarthritis was
established clinically and radiographically. Initial pain had to be
a minimum of 40/100 mm at inclusion, plus >15 mm increase
and worsening in investigator global assessment since baseline.
The actual numbers of responders for each level of response for
each drug in each trial and at each time point are shown in the
online supplement.
Table 1 gives the percentage of responders and NNTs for each
level of response for each drug in each trial and at each time
point. The percentage of responders and NNTs are also shown
in figs 1 and 2, respectively.
The percentage of patients achieving levels of pain relief with
placebo at each threshold rose between weeks 2 and 12 (table 1).
At the end of 12 weeks the proportion of patients was about
45% for a response of >15%, 35% for >30%, 25% for >50% and
15% for >70%. More patients achieved each level of response
with active drug than with placebo (table 1, fig 1). Etoricoxib
30 mg and 60 mg daily and celecoxib 200 mg daily had similar
response patterns, with constant percentages at lower response
levels but a tendency over time for the proportion achieving
>70% pain relief by 12 weeks to increase. Naproxen 1000 mg
daily and ibuprofen 2400 mg daily had different response
patterns, with stable or increasing percentages at higher levels
(>50%, >70%) but progressive decreases in the percentage
achieving lower levels of response of >15% and >30%.
Table 1 Percentage of responders with treatment/placebo and numbers needed to treat (NNTs) after 2, 4, 8 and 12 weeks
Outcome
Percentage of responders with treatment/placebo after different
numbers of weeks NNT (95% CI)
2 481 2 2 4 8 1 2
Etoricoxib 30 mg; 5 trials, 1486 patients
>15% 70/41 70/45 70/43 68/45 3.5 (2.9 to 4.2) 4.1 (3.4 to 5.2) 3.6 (3.0 to 4.4) 4.4 (3.5 to 5.7)
>30% 54/27 56/30 59/31 59/36 3.7 (3.1 to 4.5) 3.9 (3.3 to 4.9) 3.7 (3.1 to 4.5) 4.3 (3.5 to 5.6)
>50% 35/13 40/18 44/23 44/24 4.6 (3.8 to 5.6) 4.4 (3.7 to 5.5) 5.0 (4.0 to 6.5) 5.1 (4.1 to 6.9)
>70% 17/5 22/9 26/13 28/17 8.9 (7.0 to 12) 7.7 (6.0 to 11) 7.8 (6.0 to 11) 8.9 (6.3 to 15)
Etoricoxib 60 mg; 3 trials, 711 patients
>15% 77/46 76/51 73/44 71/47 3.3 (2.6 to 4.5) 4.1 (3.1 to 6.2) 3.5 (2.7 to 4.9) 4.2 (2.9 to 7.4)
>30% 61/31 63/32 60/30 59/35 3.2 (2.6 to 4.6) 3.2 (2.6 to 4.4) 3.3 (2.6 to 4.5) 4.0 (2.9 to 6.7)
>50% 43/16 46/19 47/20 44/23 3.7 (2.9 to 5.0) 3.7 (2.9 to 5.1) 3.7 (2.9 to 5.1) 4.7 (3.3 to 8.1)
>70% 25/4 27/9 30/11 30/15 4.7 (3.9 to 6.0) 5.7 (4.3 to 8.4) 5.3 (4.0 to 7.7) 6.7 (4.4 to 14)
Celecoxib 200 mg; 2 trials, 714 patients
>15% 64/42 67/45 64/40 64/40 4.6 (3.4 to 7.0) 4.5 (3.3 to 6.7) 4.2 (3.2 to 6.1) 4.2 (3.2 to 6.1)
>30% 53/27 54/29 54/30 53/31 3.9 (3.0 to 5.3) 4.0 (3.1 to 5.6) 4.1 (3.2 to 5.9) 4.7 (3.5 to 7.1)
>50% 30/12 39/18 39/22 39/22 5.6 (4.2 to 8.3) 4.8 (3.6 to 6.9) 5.9 (4.2 to 9.9) 5.8 (4.2 to 9.5)
>70% 15/6 22/10 24/13 26/16 10 (7.1 to 18) 8.7 (5.9 to 16) 9.1 (6.0 to 19) 10 (6.3 to 27)
Naproxen 1000 mg; 2 trials, 531 patients
>15% 78/54 75/57 70/48 64/47 4.2 (3.0 to 7.5) 5.6 (3.6 to 13) 4.6 (3.1 to 8.8) 5.9 (3.6 to 15)
>30% 63/35 65/36 60/35 55/35 3.5 (2.6 to 5.5) 3.5 (2.6 to 5.4) 3.9 (2.8 to 6.4) 4.8 (3.2 to 9.2)
>50% 44/20 47/22 45/22 44/23 4.1 (3.0 to 6.3) 3.9 (2.9 to 6.0) 4.3 (3.1 to 7.0) 4.8 (3.3 to 8.5)
>70% 22/5 27/10 28/12 27/15 5.9 (4.4 to 8.8) 5.8 (4.1 to 9.7) 6.1 (4.2 to 11) 8.0 (4.9 to 21)
Ibuprofen 2400 mg; 2 trials, 618 patients
>15% 69/43 65/47 60/48 58/49 3.8 (2.9 to 5.5) 5.5 (3.8 to 10) 7.8 (4.8 to 22) 11 (5.8 to 121)
>30% 49/29 51/33 51/36 49/41 5.0 (3.6 to 8.1) 5.6 (3.9 to 10) 6.6 (4.3 to 14) NS
>50% 29/14 35/20 40/24 39/27 6.5 (4.6 to 11) 6.9 (4.6 to 14) 6.4 (4.3 to 12) 8.4 (5.1 to 24)
>70% 16/6 20/8 22/13 26/18 10 (7.0 to 21) 7.9 (5.6 to 14) 11 (6.6 to 32) 13 (6.8 to 75)
Response with placebo is for placebo groups from trials in the particular comparison being made.
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very similar with etoricoxib 60 mg and 30 mg, celecoxib 200 mg
and naproxen 1000 mg (table 1, fig 2). NNT values were
between 3 and 5 over the 12 weeks of measurement. For >70%
pain relief the NNT was distinctly higher with values between 6
and 10. The pattern for ibuprofen 2400 mg was different, with
NNTs generally much higher (worse) at longer study duration
and less consistency between the various levels of response.
There were three direct comparisons, each in two trials, of
daily doses of etoricoxib 60 mg and naproxen 1000 mg,
etoricoxib 30 mg and celecoxib 200 mg, and etoricoxib 30 mg
and ibuprofen 2400 mg. No statistically significant differences
were found between them at any level of response or any
duration of treatment.
The additional reduction in the WOMAC pain subscale score
for each active treatment over placebo between the flare/
randomisation visit and end of treatment is shown in fig 3. The
smallest mean difference above placebo was 8 mm for ibuprofen
2400 mg daily and the largest was 15 mm for etoricoxib 60 mg
daily. This shows that about 60% of patients have moderate
benefit (fig 1) while average reductions in pain over placebo
appear modest.
DISCUSSION
Population mean changes have no easy resonance outside a
clinical trial. An average of 10 mm out of 100 mm (10%
improvement; fig 3) conveys no expectation of great benefit,
with little to balance against known risks. A different approach
is needed.
A pilot study of responder analysis in a single trial indicated
that it might be a useful way of reporting pain results in
osteoarthritis.
9 It suggested that at least 50% pain relief after
6 weeks of treatment could be a useful discriminator between
interventions of greater and lesser efficacy. This needs valida-
tion with regard to different levels of pain relief, and especially
duration, given that arthritis treatments are used in the medium
to long term.
IMMPACT provided recommendations for interpreting the
clinical importance of treatment outcomes in clinical trials of
chronic pain.
27 It suggested that a 10–20% decrease in pain
intensity was minimally important, >30% moderately impor-
tant and >50% substantial. This meta-analysis used these three
discriminator points, together with the even higher discrimi-
nator of >70% pain relief, to perform a responder analysis,
calculate NNTs and examine the effects of trial duration.
Figure 1 Percentage of responders over baseline at various levels of reductions in pain intensity (PR) for placebo and five active drugs over 12 weeks
of treatment.
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for all five active drugs and placebo (fig 1, table 1). Using the
IMMPACT descriptions for commonly used NSAIDs, 60–80%
of patients with osteoarthritis can expect minimally important
pain relief, 50–60% moderate pain relief, 40–50% substantial
pain relief and 20–30% extensive pain relief.
With placebo and active drugs the proportion achieving higher
levels of pain relief increased over time, perhaps due to a natural
waningofpaininherentinthe‘‘flare’’design.Thetendencytoless
responseatlowerlevelsofpain reliefovertime withnaproxenand
ibuprofen may reflect higher withdrawal rates for traditional
NSAIDs over cyclooxygenase-2 selective inhibitors.
31 32 Patients
may be balancing benefit and harm, with lower levels of relief
perhaps not worthwhile in the face of adverse events. In the
responder approach, dropouts contribute to the denominator
only,whereaswith‘‘lastobservationcarriedforward’’theyappear
to continue to benefit after withdrawal.
NNTs were comparable for pain relief of >15%, >30% and
>50%, with higher (worse) NNTs for >70% for both doses of
etoricoxib, celecoxib and naproxen. For these three drugs, NNTs
were reasonably stable over 2–12 weeks. Ibuprofen 2400 mg
daily was different, with NNT values generally increasing
(worsening) with longer duration. The longitudinal responder
analysis provides more insight than population average differ-
ences (fig 3). This apparently different behaviour with
ibuprofen 2400 mg daily did not translate into a statistically
significant difference in NNTs between ibuprofen and etori-
coxib 30 mg, nor was a significant difference found between
Figure 2 Numbers needed to treat (NNT) compared with placebo for five active drugs over 12 weeks of treatment using various levels of reductions
in pain intensity (PR) over baseline.
Figure 3 Weighted mean difference between treatment and flare/
randomisation visit for WOMAC pain subscale: active treatment minus
placebo. Shading shows upper and lower 95% confidence intervals.
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naproxen 100 mg. Establishing a dose-response in analgesic
trials is known to be difficult even where direct comparisons are
available in relatively simple models such as postoperative
pain.
33 Demonstrating an absolute difference in response of 10%
requires a substantial number of trials and patients. Confirming
statistically that ibuprofen 2400 mg is inferior to other NSAIDs
at commonly used doses in osteoarthritis will require more data.
A range of ¡0.5 NNT was proposed to determine whether an
NNT has ‘‘clinical relevance’’—whether the NNT is within
acceptable bounds of clinical ‘‘accuracy’’.
34 As u b s e q u e n tp r o p o s a l
was that ¡0.5 NNT could be used to determine that NNTs were
different.
27 Ifa numericaldifference between NNTs of 1 (eg,3.5 vs
5.0) was taken to be important, then the application to NNTs in
table 1 would begin to differentiate between drugs, with
ibuprofen particularly being judged less effective.
The results of the responder analysis achieve the same global
conclusions as the original trials—namely, that etoricoxib and
its comparators have useful analgesic properties in osteoarthri-
tis. Arguably the most important outcome from these analyses
is that, for osteoarthritis, patients and professionals can be
provided with trial data that translate into clinical practice by
using realistic estimates of the chance of achieving a particular
level of benefit. For pain, a mean difference of 10 mm over
placebo translates into about 40% having substantial benefit
and 30% not having even minimal benefit. Most people with
osteoarthritis treated with an NSAID at an appropriate dose can
expect to get at least a minimal benefit (though 1 in 5 will not),
almost 1 in 2 can expect a substantial benefit and about 1 in 5
an extensive benefit. The prospect of a 1 in 2 chance of
substantial benefit has considerably more impact than an
average 10% improvement in pain. Moreover, the information
is conveyed in terms of both the likelihood of benefit (1 in 2)
and the extent of the benefit (substantial).
Patients and professionals are interested in the known
associated risks of both common and rare harm. These, too,
can be conveyed in terms of likelihood of harm and its
consequences.
35 Balancing benefit and harm is easier when
common language describes both. Providing information about
the chance of response at various thresholds might produce a
more realistic appreciation of benefits and risks of treatment.
There is, of course, the caveat that these results come from flare
designs in clinical trials where patient selection criteria may
make the population different (less comorbidity, perhaps) than
a clinical practice population.
Responders are defined not just by the level of response but
by the outcome used to define response. We chose the WOMAC
pain subscale, combining pain associated with walking, climb-
ing stairs, sitting, lying down and at night while in bed.
Whether pain is the most appropriate outcome for responder
analysis or whether function, sleep, quality of life or compound
outcomes like the OMERACT-OARSI set of responder criteria
36
are preferable remains to be examined. Finally, this type of
analysis may differentiate between treatments in a manner that
is not possible with population mean changes in pain intensity,
and discriminatory power may reside in different outcomes.
Responder analysis looks promising and much more helpful
than an average change of a few millimetres based on
populations of responders combined with non-responders.
CONCLUSION
Population mean change in pain intensity reported in clinical
trials may be difficult to translate into clinical decision-making
and patient expectations of benefit. Responder analyses and
NNTs calculated from them are reproducible for different levels
of response and over at least 12 weeks of treatment with
effective drugs. This offers the possibility of providing patients
and professionals with information on the chance of achieving
particular degrees of pain relief, improving clinical decision-
making and patient communication.
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